Oral 17β-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size

Atherosclerosis

Volumn 155, Issue 2, 2001, Pages 425-430

  Tangney, Christine C ^a   Mosca, Lori J ^b   Otvos, James D ^c   Rosenson, Robert S ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

HDL particle size; Hormone replacement therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; VERY LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; ESTROGEN THERAPY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PILL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; HORMONE SUBSTITUTION; HORSE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HORSES; HUMANS; LIPOPROTEINS, HDL; MAGNETIC RESONANCE SPECTROSCOPY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PARTICLE SIZE; POSTMENOPAUSE;

EID: 0034745323     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00577-3     Document Type: Article

References (35)

1. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high-density lipoprotein metabolism
2. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women
3. Estrogen treatment and human lipoprotein metabolism
4. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women
5. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis
6. Association of small, dense low-density lipoprotein particles with the incidence of coronary artery disease in men and women
7. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease
8. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease
9. High-density lipoprotein: Relations to metabolic parameters and severity of coronary artery disease
10. Associations of age, adiposity, alcohol intake and estrogen therapy with high-density subclasses
11. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
12. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
13. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
14. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women
15. Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women
16. Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease
17. Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes
18. Changes in the low-density lipoprotein profile during 17β-estradiol-dydrogesterone therapy in postmenopausal women
19. Impact of combined hormone replacement therapy on serum lipid metabolism: New aspects
20. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles: Comparison of transdermal and oral treatment regimens
21. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestin interventions (PEPI) trial
22. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single rapid measurement
23. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
24. Effects of tourniquet technique, order of draw, and sample storage on plasma fibrinogen
25. Effects of tourniquet application on plasma viscosity measurements
26. Characterization of low-density lipoprotein subclasses: Methodologic approaches and clinical relevance
27. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins
28. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B
29. Hepatic lipase influences high density lipoprotein subclass distribution in normotriglyceridemic men: Genetic and pharmacological evidence
30. Unusual HDL subclass distribution during late pregnancy
31. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations
32. Change in LDL particle size is associated with change in plasma triglyceride concentration
33. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients
34. High density lipoprotein subfractions in non-insulin dependent diabetes mellitus and coronary artery disease
35. Effect of gender and menopausal status on plasma lipoprotein subspecies and particle sizes